# Outpatient Treatment With CoVid-19 With Prexablu

> **NCT04619290** · PHASE1 · UNKNOWN · sponsor: **Hospital Reg. Lic. Adolfo Lopez Mateos** · enrollment: 46 (estimated)

## Conditions studied

- Sars Cov 2

## Interventions

- **DRUG:** Sublingual Methylene blue
- **OTHER:** Control patients

## Key facts

- **NCT ID:** NCT04619290
- **Lead sponsor:** Hospital Reg. Lic. Adolfo Lopez Mateos
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-12
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2020-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04619290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04619290, "Outpatient Treatment With CoVid-19 With Prexablu". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04619290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*